Presented at the AACR-NCI-EORTC conference. After initial responses to tyrosine kinase inhibitors (TKIs), NSCLC patients harboring EGFR activating mutations inevitably progress, with the “gatekeeper” EGFR T790M resistance mutation accounting for approximately 60% of cases of acquired resistance (AR) to TKIs. ...
Read More »